NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis $0.91 +0.05 (+5.26%) Closing price 04:00 PM EasternExtended Trading$0.90 -0.01 (-1.04%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Akebia Therapeutics Stock (NASDAQ:AKBA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Akebia Therapeutics alerts:Sign Up Key Stats Today's Range$0.85▼$0.9250-Day Range$0.84▼$1.3552-Week Range$0.81▼$3.20Volume7.50 million shsAverage Volume5.81 million shsMarket Capitalization$252.31 millionP/E RatioN/ADividend YieldN/APrice Target$3.90Consensus RatingHold Company Overview Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for patients with kidney disease and related complications. The company’s portfolio centers on therapies for anemia associated with chronic kidney disease (CKD), a condition that can result from reduced kidney function and insufficient production of erythropoietin. Akebia’s primary product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In the United States, Vafseo is approved to treat anemia due to CKD in adults who have been receiving dialysis for at least three months. The product is designed to stimulate the body’s natural response to low oxygen levels and support red blood cell production. The company also markets Auryxia (ferric citrate), which is approved in the United States for controlling serum phosphorus levels in adults with CKD on dialysis and for treating iron-deficiency anemia in certain adults with non-dialysis-dependent CKD. Akebia gained Auryxia through its combination with Keryx Biopharmaceuticals in 2018. The company is headquartered in Cambridge, Massachusetts, and serves patients primarily through its commercial operations in the United States, while pursuing international opportunities through partnerships and licensing arrangements. John P. Butler has served as Akebia’s president and chief executive officer since 2016. The company’s operations and research activities remain focused on renal medicine, including the development and commercialization of therapies intended to address significant unmet needs among people with CKD.AI Generated. May Contain Errors. Read More Akebia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreAKBA MarketRank™: Akebia Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 298th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingAkebia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAkebia Therapeutics has a consensus price target of $3.90, representing about 328.3% upside from its current price of $0.91.Amount of Analyst CoverageAkebia Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Akebia Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Akebia Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.27) per share.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 7.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Akebia Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.73% of the float of Akebia Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 2.76, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akebia Therapeutics has recently decreased by 10.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News SentimentN/A News SentimentAkebia Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Akebia Therapeutics this week, compared to 4 articles on an average week.Search Interest7 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows6 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders4.30% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by Institutions33.92% of the stock of Akebia Therapeutics is held by institutions.Read more about Akebia Therapeutics' insider trading history. Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKBA Stock News HeadlinesAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2026 | globenewswire.comAkebia Therapeutics (NASDAQ:AKBA) & MDxHealth (NASDAQ:MDXH) Head to Head ComparisonSeptember 27, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 5 at 1:00 AM | Profits Run (Ad)Akebia Doses First Patient In Phase 2 Trial Of Ebribafusp For Rare Kidney DiseasesSeptember 14, 2026 | rttnews.comAkebia Therapeutics Doses First Patient in Phase 2 Ebribafusp TrialSeptember 14, 2026 | finance.yahoo.comAkebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney DiseasesSeptember 14, 2026 | globenewswire.comWestPark Capital initiates coverage of Akebia Therapeutics with buy ratingSeptember 9, 2026 | msn.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | globenewswire.comSee More Headlines AKBA Stock Analysis - Frequently Asked Questions How have AKBA shares performed this year? Akebia Therapeutics' stock was trading at $1.61 on January 1st, 2026. Since then, AKBA shares have decreased by 43.4% and is now trading at $0.9105. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. The biopharmaceutical company earned $49.13 million during the quarter, compared to the consensus estimate of $48.85 million. Akebia Therapeutics had a negative trailing twelve-month return on equity of 88.88% and a negative net margin of 13.54%. Read the conference call transcript. When did Akebia Therapeutics IPO? Akebia Therapeutics (AKBA) raised $91 million in an initial public offering on Thursday, March 20th 2014. The company issued 5,882,353 shares at $14.00-$17.00 per share. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and ExxonMobil (XOM). Company Calendar Last Earnings8/05/2026Today10/05/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 12 days, AKBA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AKBA CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees194Year Founded2007Price Target and Rating Average Price Target for Akebia Therapeutics$3.90 High Price Target$6.00 Low Price Target$1.00 Potential Upside/Downside+328.3%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.34 million Net Margins-13.54% Pretax Margin-12.71% Return on Equity-88.88% Return on Assets-7.74% Debt Debt-to-Equity Ratio0.99 Current Ratio1.43 Quick Ratio1.35 Sales & Book Value Annual Sales$236.20 million Price / Sales1.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book7.59Miscellaneous Outstanding Shares277,110,000Free Float265,190,000Market Cap$252.31 million OptionableOptionable Beta0.18 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:AKBA) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
